顆粒酶B(GZMB)重組蛋白
Recombinant Granzyme B (GZMB)
GZM-B; HLP; CTLA1; CCPI; CGL1; CSP-B; CSPB; CTSGL1; SECT; Granzyme 2; Cytotoxic T-Lymphocyte-Associated Serine Esterase 1; Fragmentin 2; Cytotoxic Serine Protease B
- 編號RPA600Po01
- 物種Sus scrofa; Porcine (Pig，豬)相同的名稱，不同的物種。
- 來源原核表達
- 宿主E.coli
- 內(nèi)毒素水平<1.0EU/µg(LAL法測定)
- 亞細胞定位細胞質(zhì)
- 預(yù)測分子量29.2kDa
- 實際分子量29kDa(差異分析請參閱說明書)
- 片段與標簽Gly19~Leu246 with N-terminal His Tag
- 緩沖液成份PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
- 性狀凍干粉
- 純度> 90%
- 等電點10.2
- 應(yīng)用Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白，請參見活性蛋白。 - 下載英文說明書 中文說明書
- 規(guī)格10μg50μg200μg1mg5mg
- 價格¥ 1128¥ 2820¥ 5640¥ 16920¥ 42300
- 欲了解實際交易價格和更多情況，請與當?shù)亟?jīng)銷商聯(lián)系!
產(chǎn)品包裝(模擬)
產(chǎn)品包裝(模擬)
Figure . Gene Sequencing (extract)
Figure. SDS-PAGE
通過ISO 9001、ISO 13485質(zhì)量體系認證
序列
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲存
避免反復(fù)凍融。2-8°C不超過一個月，-80°C不超過12個月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定，具體方法如下：在37°C孵育48小時，沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當?shù)臈l件下存儲，損失率低于5%。
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種：Sus scrofa; Porcine (Pig，豬) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPA600Po01 | 顆粒酶B(GZMB)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| APA600Po01 | 顆粒酶B(GZMB)活性蛋白 | Cell?culture;?Activity?Assays. |
參考文獻
| 雜志 | 參考文獻 |
| International Journal of Cancer | Effective immunotherapy of rat glioblastoma with prolonged intratumoral delivery of exogenous heat shock protein Hsp70[Pubmed:24691976] |
| Biol Pharm Bull. | Z-100, an Immunomodulatory Extract of Mycobacterium tuberculosis Strain Aoyama B, Prevents Spontaneous Lymphatic Metastasis of B16-BL6 Melanoma[Pubmed:24818259] |
| Journal of Dermatological Science | Relationships?among?plasma?granzyme?B?level,?pruritus?and?dermatitis?in?patients?with?atopicdermatitis.[pubmed:27686401] |
| Oncotarget | Tumor-derived granzyme B-expressing neutrophils acquire antitumor potential after lipid A treatment[Pubmed:29983866] |
| Theranostics | A novel Granzyme B nanoparticle delivery system simulates immune cell functions for suppression of solid tumors[Pubmed: 31695790] |
| Am J Transl Res | Combined treatment with epigenetic agents enhances anti-tumor activity of T cells by upregulating the ACRBP expression in hepatocellular carcinoma[34377237] |